首页 | 本学科首页   官方微博 | 高级检索  
     


Nimotuzumab Dosing and Outcomes in Locally Advanced Head and Neck Cancer
Affiliation:1. Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK;2. West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK;3. Division of Cancer Sciences, University of Manchester, The Christie NHS Foundation Trust, Manchester, UK;3. Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK;4. The Christie NHS Foundation Trust, Manchester, UK;5. University of Manchester, Manchester, UK;7. Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK;1. Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK;2. West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK;3. Cancer Research UK Beatson Institute, Glasgow, UK;1. Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China;2. Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China;3. State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong SAR, China;4. Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan;5. Department of Clinical Oncology, Queen Mary Hospital, Hong Kong SAR, China;1. The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, Ontario, Canada;2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;3. Ottawa Hospital Research Institute, Ottawa, Ontario, Canada;4. University Health Network, Toronto, Ontario, Canada;5. Children''s Hospital of Eastern Ontario, Ottawa, Ontario, Canada;7. Department of Surgery, Centre Hospitalier de l’Université de Montréal, Montreal, Quebec, Canada;11. Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, Ontario, Canada;12. Department of Surgery, McMaster University, Hamilton, Ontario, Canada;8. Division of Urology, Department of Surgery, Western University, London, Ontario, Canada;9. Department of Surgery, Western University, London, Ontario, Canada;71. Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada;112. Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada;123. Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada;84. Division of Urology, McGill University, Montreal, Quebec, Canada;95. Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada;77. Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada;1111. Laval University, Quebec City, Quebec, Canada;1212. Division of Medical Oncology, The Ottawa Hospital Cancer Centre and the University of Ottawa, Ottawa, Ontario, Canada;1. Department of Clinical Oncology, University Hospitals Bristol NHS Foundation Trust, Bristol Haematology and Oncology Centre, Bristol, UK;2. University Hospitals Bristol NHS Foundation Trust, Bristol, UK;3. National Radiotherapy Trials Quality Assurance Group (RTTQA), Mount Vernon Hospital, Northwood, UK
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号